Endometrial Cancer Treatment Market by Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery), by Distribution Channel (Hospitals, Retail Pharmacies, Others) and Geography      

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Endometrial Cancer Treatment Market size was valued at USD 26.8 billion in 2021, growing at a CAGR of 4.8% during the forecast period 2022-28. Endometrial cancer is the most common female genital cancer that begins in endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by the pelvic examination, ultrasound scanning and other techniques. Treatment may include, chemotherapy, radiation therapy or hormonal therapy.   This report studies global endometrial cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global endometrial cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products.In September 2019, the US FDA approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.

Endometrial Cancer Treatment Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Endometrial Cancer Treatment Market Dynamics Drivers and Restraints

Primary drivers for endometrial cancer treatment market include increase in the prevalence of endometrial cancer and increase in awareness and availability of minimally invasive treatments such as radiation therapy. According to American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed. In addition, increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer treatment globally. In addition growing obesity in female population also one of the risk factor for growing prevalence of endometrial cancer worldwide. However, the side effects related to the chemotherapy, divergent nature of cancer and stringent regulatory requirements for the development of new treatments for the cancer are projected to hamper the market growth over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Endometrial Cancer Treatment Market Segmentation

  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Others
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa


Frequently Asked Questions

The endometrial cancer treatment market is projected to expand at a CAGR of 4.8% during the forecast period

Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Hoffmann-La Roche AG (Switzerland)

North-America is the fastest-growing region for the endometrial cancer treatment market


[urltag url='request-table-of-content']

  • Abbott Laboratories (U.S.)
  • Becton, Dickinson and Company (U.S.)
  • Ariad Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline Plc (U.K.)
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • Sanofi (France)